ITP Clinical Trial
Official title:
Anti-BCMA CAR T-Cell Therapy for Relapsed/Refractory Immune Thrombocytopenia
Verified date | March 2022 |
Source | The First Affiliated Hospital of Soochow University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy(BCMA CAR-T)for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).
Status | Recruiting |
Enrollment | 5 |
Est. completion date | June 30, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Refractory ITP defined according to the recent consensual criteria ( 'Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)'), or relapse ITP defined as ITP patients who have responded to first-line therapy (glucocorticoids or immunoglobulins) and anti-CD20 monoclonal antibody, but cannot maintain the response. - Ages 18-65 years inclusive. - Adequate venous access for apheresis or venous blood and no other contraindications for leukocytosis. - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. - Subjects should have full capacity for civil conduct, understand necessary information,sign the informed consent form voluntarily,and have good corporation with the content of this research protocol. Exclusion Criteria: - Secondary ITP. - Patients with a known history or prior diagnosis of arterial thrombosis (such as cerebral thrombosis, myocardial infarction, etc.), or comorbidity of venous thrombosis (such as deep vein thrombosis, pulmonary embolism), or are using anticoagulant/antiplatelet drug at the beginning of trial. - Patients with a known history or prior diagnosis of serious cardiovascular disease. - Patients with uncontrolled infection, organ dysfunction or any uncontrolled active medical disorder that would preclude participation as outlined. - Patients with malignancy or history of malignancy. - Failed T cell expansion test. - During screening, hemoglobin <100g/L; absolute value of neutrophil count <1.5×10^9/L. - During screening, serum creatinine concentration > 1.5x the upper limit of the normal range, total bilirubin > 1.5x the upper limit of the normal range, alanine aminotransferase and aspartate aminotransferase > 3x the upper limit of the normal range, Left ventricular ejection fraction = 50% by echocardiography, Pulmonary function = grade 1 dyspnea (CTCAE v5.0), blood oxygen saturation<91% without oxygen inhalation. - Prothrombin time (PT) or prothrombin time-international normalized ratio (PT-INR) or activated partial thromboplastin time (APTT) exceeding 20% of the normal reference range; or a history of coagulation abnormalities other than ITP. - Either HIV antibody or syphilis antibody is positive; hepatitis C antibody is positive and the detection of HCV-RNA exceeds the laboratory test upper reference limit; hepatitis B surface antigen is positive and the detection of HBV-DNA exceeds the laboratory test upper reference limit. - Participated in other clinical studies within 3 months before this CAR-T cell infusion. - Patients is pregnant or breastfeeding, or planning pregnancy. - Patients is fertile and the investigator determines the case is inappropriate to participate. - History of severe drug allergy or known allergy to CAR-T treatment related drugs. - Suspected or established alcohol, drug or drug abuse. - The investigator judges that it is not suitable to participate in this trial. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Soochow University | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | overall response | The number of participants who achieved CR (defined as platelet count=100x10e9/L) and PR (defined as platelet count =30x10e9/L and at least a 2-fold increase the baseline count and absence of bleeding) at follow-up. | 6-months | |
Secondary | Time to response | Time since infusion of CAR T-cells to the time to achieve the response. | 6-months | |
Secondary | Duration of response | Period from the achievement of response to the loss of response. | 6-months | |
Secondary | Incidence of adverse events | Adverse events will be assessed daily during the first 2 weeks after the BCMA CAR-T treatment, and monthly thereafter. Adverse events will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. | 6-months | |
Secondary | Evaluation of bleeding events | Bleeding events will be evaluated according to Bleeding rating system of ITP('Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)'). | 6-months | |
Secondary | Evaluation of concomitant therapy | Duration of discontinuation or dose reduction of concomitant treatment,and the degree of decrease of combined treatment from the baseline in patients. | 6-months | |
Secondary | Evaluation of health-related quality of life | Health-related quality of life will be evaluated according to ITP-PAQ (Primary Immune Thrombocytopenia Patient Assessment Questionnaire). | 6-months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05281068 -
The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
|
Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT02914054 -
Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone
|
Phase 2/Phase 3 | |
Recruiting |
NCT05116423 -
Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
|
||
Terminated |
NCT04904276 -
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
|
||
Recruiting |
NCT04747080 -
The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
|
Phase 2 | |
Not yet recruiting |
NCT04482777 -
IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
|
||
Recruiting |
NCT05446831 -
Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia
|
Phase 2 | |
Active, not recruiting |
NCT04703621 -
The DART Study- Daratumumab Treatment in ITP
|
Phase 2 | |
Recruiting |
NCT05118126 -
Gut Microbiota in ITP
|
||
Active, not recruiting |
NCT04943042 -
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
|
||
Completed |
NCT04089267 -
Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)
|
Phase 4 | |
Recruiting |
NCT04735588 -
Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP
|